Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-based Treatment for Children With Unresectable Localized Soft Tissue Sarcomas
NCT02784015Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- May 2016
- Primary completion
- May 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin, etoposide, doxorubicin, cyclophosphamide, ifosfamide in soft tissue sarcoma (STS), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
cisplatinetoposidedoxorubicincyclophosphamideifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02784015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784015.